Phenotypic and genotypic adaptations in Pseudomonas aeruginosa biofilms following long-term exposure to an alginate oligomer therapy. Pseudomonas aeruginosa biofilms response to alginate therapy

Chronic Pseudomonas aeruginosa lung infections in cystic fibrosis (CF) evolve to generate environmentally adapted biofilm communities, leading to increased patient morbidity and mortality. OligoG CF-5/20, a low molecular weight inhaled alginate oligomer therapy, is currently in Phase IIb/III clinical trials in CF patients. Experimental evolution of P. aeruginosa in response to OligoG CF-5/20 was assessed using a bead biofilm model allowing continuous passage (45 days; ~245 generations). Mutants isolated after OligoG CF-5/20 treatment typically had a reduced biofilm forming ability and altered motility profile. Genotypically, OligoG CF-5/20 provided no selective pressure on genomic mutations within morphotypes. Chronic exposure to azithromycin, a commonly prescribed antibiotic in CF patients, ± OligoG CF-5/20 in the biofilm evolution model also had no effect on rates of resistance acquisition. Interestingly however, cross-resistance to other antibiotics (e.g. aztreonam) was reduced in the presence of OligoG CF-5/20. Collectively, these findings show no apparent adverse effects from long-term exposure to OligoG CF-5/20, instead resulting in both fewer colonies with MDR-associated phenotypes and improved antibiotic susceptibility of P. aeruginosa.